Asalyxa Bio Closes Seed Financing to Advance Lead Program into First-in-Human Clinical Studies

24 Feb, 2021

Asalyxa Bio Closes Seed Financing to Advance Lead Program into First-in-Human Clinical Studies
Photo by Mathieu Stern on Unsplash

– Asalyxa Bio closed a $2m seed financing round to advance its lead program into first-in-human clinical trials.
– The financing was led by Research Bridge Partners, co-led by ID Ventures, and also included Michigan Rise Pre-Seed Fund III, BRCC of Western Michigan University, Ann Arbor Spark, Woodward Angels and other undisclosed investors.
– Proceeds from the financing will be used to advance Asalyxa Bio’s lead development candidate, ASX-100, into first-in-human clinical trials.
– Asalyxa Bio’s drug development programs are based on the company’s proprietary PANTHER technology platform, which enables the targeted delivery of therapeutic compounds directly to neutrophils and other key immune cells.

Biotechnology North America
Crunchbase icon

Content report

The following text will be sent to our editors: